| answer text |
<p>The voluntary scheme for branded medicines pricing, access and growth (VPAG) represents
a landmark deal which will enable patients to access the latest lifesaving treatments
more consistently, boost the United Kingdom’s position as a global superpower in advanced
healthcare, technology and clinical research, and is set to save the National Health
Service £14 billion over five years, in medicines costs.</p><p> </p><p>The VPAG also
introduces a new payment mechanism in which older medicines that are yet to realise
price reductions, will pay a higher payment rate. Those medicines that have realised
price reductions will pay a lower payment rate. This ensures that the scheme is strictly
pro-innovation and pro-competition, which will enhance health outcomes for patients
and deliver value for money for taxpayers. It includes an additional £400 million
of investment by industry over the five years of the scheme, for the VPAG Investment
Programme.</p>
|
 |
